SELL and inflammatory bowel disease: CD62L (L-selectin) shedding is the first validated test of functional blockade of TNFα in patients with IBD for long-term prediction of stable disease state under anti-TNF inhibition; this live assay seems to perform better than TL and ADA measurements.